drugset
drugset / Trial / NCT03627065

A Study of INCB050465 in Primary Sjögren's Syndrome

NCT03627065 ↗

Phase 2 Completed 10 enrolled Incyte Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).

Timeline

Start
2019-02-28
Primary completion
2019-12-07
Completion
2020-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule — Oral

Indications

Sjogren syndrome